Theralase Technologies Inc. CEO Roger DuMoulin-White discussed recent research advancements related to cancer treatment.
He highlighted that current chemotherapies and drugs, while initially effective, tend to lose their efficacy over time due to a phenomenon known as chemo resistance. This leads to a situation where patients no longer benefit from the treatment but continue to suffer from its side effects.
Theralase Technologies is focusing on addressing this issue by investigating ways to improve the long-term effectiveness of these treatments. Further details on the specific approaches or findings are covered in the full interview.
#ProactiveInvestors #TheralaseTechnologies, #CancerResearch, #ChemoResistance, #CancerTreatment, #Biotechnology, #Pharmaceuticals, #Oncology, #DrugDevelopment, #CancerTherapies, #MedicalResearch, #HealthInnovation, #CEOInterview, #CancerCare, #DrugEfficacy, #Therapeutics, #ClinicalResearch, #MedicalBreakthrough, #HealthTech, #PatientCare, #Theralase #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
